Envoy MedicalCOCH -4.82%24 Days Payable is 673.44 as of Mar. 2026, which is 10% above its 10-year median of 609.80. GuruFocus rates COCH with a GF Score™ of 24/100 and a GF Value™ of $1.13 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Envoy Medical ranks better than 94.72% on this metric.
The historical rank and industry rank for Envoy Medical's Days Payable or its related term are showing as below:
COCH'
s Days Payable Range Over the Past 10 Years
Min: 313.74 Med: 609.8 Max: 954.68
Current: 803.84
During the past 5 years, Envoy Medical's highest Days Payable was 954.68. The lowest was 313.74. And the median was 609.80.
COCH's Days Payable is ranked better than 94.72% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs COCH: 803.84
Envoy Medical's Days Payable
increased
from Mar. 2025 (669.03) to Mar. 2026 (673.44).
It may suggest that Envoy Medicaldelayed paying its suppliers.
Envoy Medical Days Payable Related Terms
Envoy Medical Days Payable Historical Data
* Premium members only.
The historical data trend for Envoy Medical's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Envoy Medical's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Envoy Medical Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Envoy Medical's Days Payable distribution charts can be found below:
* The bar in red indicates where Envoy Medical's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Envoy Medical's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Envoy Medical (COCH) has a Days Payable of 673.44 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Envoy Medical and its competitors. This is 10% above median its historical median of 609.80. Over the past decade, Envoy Medical's Days Payable has ranged from 313.74 to 954.68. According to the industry distribution chart, Envoy Medical ranks #42 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 5.3%.
Is Envoy Medical's Days Payable too high?
Envoy Medical's current Days Payable of 673.44 is 10% above median its 10-year median of 609.80. Over the past 10 years, this metric has ranged from a low of 313.74 to a high of 954.68. The Medical Devices & Instruments industry median Days Payable is 68.07. Envoy Medical's value of 673.44 is 889.3% above this industry median. Based on the distribution chart, Envoy Medical ranks #42 out of 795 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Envoy Medical has a GF Score™ of 24/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Envoy Medical's Days Payable compare to SRTS and QTI?
According to the Medical Devices & Instruments industry distribution chart, Envoy Medical ranks #42 out of 795 companies for Days Payable. This places Envoy Medical in the top 5% of its industry — outperforming the majority of peers. The industry median Days Payable is 68.07. Envoy Medical's value of 673.44 is 889.3% above this benchmark. Historically, Envoy Medical's own Days Payable has ranged from 313.74 to 954.68 over the past decade. While the company's 10-year median is 609.80 vs. the industry median of 68.07, Envoy Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Envoy Medical's current Days Payable of 673.44 is 889.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Envoy Medical and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Envoy Medical's current Days Payable is 673.44, which is 10% above median its own 10-year median of 609.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Envoy Medical stock overvalued right now?
Based on GuruFocus' analysis, Envoy Medical (COCH) is currently considered Possible Value Trap. The stock's GF Value™ is $1.13, compared to a current price of $0.77 — trading 32% below its estimated fair value. The current Days Payable is 673.44, which is 10% above median its 10-year median of 609.80 and 889.3% above the Medical Devices & Instruments industry median of 68.07. Envoy Medical's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Envoy Medical (COCH), the current Days Payable is 673.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Envoy Medical (COCH) Overvalued in 2026?
Based on GuruFocus' analysis, Envoy Medical stock appears to be undervalued.
The current stock price of $0.77 is trading 32% below its estimated GF Value™ of $1.13.
GuruFocus considers Envoy Medical to be Possible Value Trap.
Key valuation signals for COCH:
Days Payable: 673.44 (10% above median its 10-year median of 609.80)
GF Value™: $1.13 vs. price of $0.77 (32% below fair value)
Industry Position: 889.3% above the Medical Devices & Instruments median (#42 of 795)
No single metric tells the full story. See the COCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
24GF Score
Get the complete analysis for COCH
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COCH has been successfully added to your 
